Search Results
Your search for ,twO matches 12333 pages
Showing 5401 - 5450Addition of Durvalumab to Etoposide Plus Platinum Chemotherapy for Extensive-Stage SCLC
This week, we’ll review an interim analysis of the CASPIAN trial, which evaluated the addition of durvalumab to etoposide plus platinum chemotherapy for extensive-stage small cell lung cancer. Then, we’ll talk about two recently issued guidelines on screening for colorectal cancer. Lastly, we’ll...
How Patients Add Life to Their Days
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Deep Learning Assists in Detection of Lung Nodule Locations, Characteristics
A computer-aided diagnosis system using deep-learning analysis to detect lung lesion locations and quantitatively characterize the lesions on computed tomography (CT) images offered a fast and convenient approach for assisting radiologists in the diagnosis of lung nodule pathologies. These findings ...
Immunotherapy Combinations Redefine Outcomes for Patients With Advanced Renal Cell Carcinoma
The treatment landscape for patients with advanced renal cell carcinoma has changed drastically over the past several years with the introduction of many new therapeutic options for patients. The revolution began with the U.S. Food and Drug Administration (FDA) approval of nivolumab and ipilimumab...
CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
As reported in The Lancet Oncology by Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues, extended follow-up of the phase III CheckMate 214 trial has shown maintained survival benefit of first-line nivolumab/ipilimumab vs sunitinib among patients with...
LEAD Conference Awards 2019 Woman Oncologist of the Year
Claire Verschraegen, MD, was named the 2019 Woman Oncologist of the Year, and Shikha Jain, MD, FACP, received the 2019 Rising Star award at the first-ever Leadership Empowerment and Development: Enriching Experiences for Women in Hematology and Oncology (LEAD) Conference, hosted by Bio Ascend. An ...
Machine-Learning Model May Predict Unplanned Hospitalizations After Radiation Therapy for Gastrointestinal Cancer
Unplanned hospitalizations may be common among patients with cancer, but they diminish quality of care while racking up high costs for patients and the health-care system alike. According to data presented at the 2019 ASCO Quality Care Symposium, however, a new predictive model may help providers...
Personalized Treatment Approaches on the Horizon for Myelodysplastic Syndromes
Despite the spate of recent drug approvals in blood cancer, it’s been more than 13 years since the U.S. Food and Drug Administration (FDA) has approved a treatment for myelodysplastic syndromes (MDS), a bone marrow disorder characterized by ineffective hematopoiesis. Nevertheless, data from a...
Abemaciclib Benefits Patients With HER2-Positive Breast Cancer in monarcHER Trial
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are associated with a robust benefit in patients with hormone receptor–positive, HER2-negative breast cancer, but now the monarcHER trial has confirmed their benefit in the HER2-positive population. The new findings were reported at the...
Studies Report Efficacy of Proton Radiotherapy for Hepatocellular Carcinoma
Two new studies published in the International Journal of Radiation Oncology • Biology • Physics focused on the use of proton radiation therapy to treat patients with hepatocellular carcinoma. The first study, by Sanford et al, found that proton radiation may extend overall survival compared to...
Ravi Thadhani, MD, MPH, Named Chief Academic Officer at Partners HealthCare
Ravi Thadhani, MD, MPH, was named Chief Academic Officer at Partners HealthCare, starting November 11, 2019. Dr. Thadhani most recently served as Vice Dean of Research and Graduate Research Education at Cedars-Sinai Medical Center in Los Angeles. Prior to that, he served as Associate Director of...
Lorlatinib in Advanced ROS1-Positive NSCLC
As reported by Alice T. Shaw, MD, and colleagues in The Lancet Oncology, a phase I/II trial has shown overall and intracranial activity of the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib in patients with advanced ROS1-positive non–small cell lung cancer (NSCLC). Lorlatinib...
High-Dose Bevacizumab for Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
In a phase II trial reported in the Journal of Clinical Oncology, Plotkin et al found that high-dose bevacizumab induction therapy did not appear to produce better outcomes compared with lower-dose treatment in patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas. As...
ADMIRAL: Gilteritinib vs Chemotherapy in Relapsed or Refractory FLT3-Mutated AML
As reported in The New England Journal of Medicine by Perl et al, the phase III ADMIRAL trial showed improved overall survival with the oral FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib vs salvage chemotherapy in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia...
PAOLA-1 Trial: Front-Line Olaparib/Bevacizumab Maintenance Benefits Women With Advanced Ovarian Cancer
In women with newly diagnosed ovarian cancer, front-line maintenance therapy with olaparib plus bevacizumab reduced the risk of disease progression by 41% overall and by 69% in the subset of patients with BRCA-mutated disease, vs bevacizumab and placebo, in the phase III PAOLA-1/ENGOT-ov25 trial...
Is There a Difference in Breast Cancer Recurrence Rates After Surgery With Regional vs General Anesthesia?
In a trial reported in The Lancet, Sessler et al found no difference in breast cancer recurrence after surgery with regional anesthesia-analgesia using paravertebral block and propofol vs general anesthesia with the volatile anesthetic sevoflurane and opioid analgesia. They also found no difference ...
IMvigor130 Trial: Atezolizumab Plus Chemotherapy for Metastatic Urothelial Cancer
Treatment with atezolizumab plus chemotherapy extended progression-free survival by 1.9 months vs chemotherapy alone in patients with metastatic urothelial cancer, according to the early results of the IMvigor130 trial, which were presented at the European Society for Medical Oncology (ESMO)...
DNA Vaccine for Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer
In a phase II study reported in the Journal of Clinical Oncology, McNeel et al found that a DNA vaccine (pTVG-HP) encoding prostatic acid phosphatase did not improve 2-year metastasis-free survival vs control treatment in patients with progressive, nonmetastatic, castration-sensitive prostate...
FDA Office of Hematology Oncology Products Reorganizes, Renamed Office of Oncologic Diseases
As part of modernization plans approved in September 2019, the U.S. Food and Drug Administration (FDA) office responsible for reviewing applications for new and existing cancer therapies has reorganized and been renamed. The Center for Drug Evaluation and Research (CDER) Office of Hematology and...
Continuous Therapy for Multiple Myeloma Offers Survival Advantage, but Questions Remain
The number of approved agents in multiple myeloma has skyrocketed in recent years, leading to significant improvements in survival, but questions remain regarding the optimal duration of treatment. Although traditionally limited to a fixed number of cycles due to accumulating toxicity, novel agents ...
Levofloxacin Prophylaxis During Treatment of Newly Diagnosed Multiple Myeloma
In the phase III TEAMM trial reported in The Lancet Oncology, Drayson et al found that prophylactic treatment with levofloxacin during the first 12 weeks of multiple myeloma treatment in newly diagnosed patients was associated with a significant reduction in first febrile episodes or death from any ...
Targeted Therapy Moves Into Metastatic Castration-Resistant Prostate Cancer With Strong Showing by Olaparib and Rucaparib
Treatment with olaparib delayed disease progression, and early survival data suggest a positive trend in favor of olaparib compared with newer hormonal agents in men with pretreated metastatic castration-resistant prostate cancer and homologous recombinant repair genetic alterations—specifically...
Patient-Reported Outcomes Observed With Durvalumab Treatment After Chemoradiotherapy for Stage III Unresectable NSCLC
As reported in The Lancet Oncology by Hui et al, no clinically important differences in patient-reported outcomes were observed among patients receiving durvalumab vs placebo after chemoradiation for stage III unresectable non–small cell lung cancer (NSCLC) in the phase III PACIFIC trial. The...
Omitting Radiation From Treatment for Early-Stage Hodgkin Lymphoma Increases Risk of Recurrence
Two presentations at the American Society for Radiation Oncology (ASTRO) Annual Meeting offered more evidence that omitting radiation therapy leads to higher rates of recurrence for patients with early-stage Hodgkin lymphoma.1,2 Both studies involve work by the German Hodgkin Study Group among...
AACR-NCI-EORTC: Investigational KRAS G12C Inhibitor for KRAS-Mutant Solid Tumors
The investigational KRAS G12C inhibitor MRTX849 yielded clinical responses in patients with non–small cell lung cancer (NSCLC) and colorectal cancer harboring KRAS G12C mutations, according to data from a phase I clinical trial presented at the AACR-NCI-EORTC International Conference on Molecular...
AACR-NCI-EORTC: Selumetinib for Adult Patients With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
The investigational MEK inhibitor selumetinib showed clinical activity in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, according to preliminary results from an ongoing phase II study presented at the AACR-NCI-EORTC International Conference on Molecular...
Association Between Prior Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy Outcomes
In a study presented in a brief report in JAMA Oncology, David J. Pinato, MD, PhD, and colleagues found that past but not concurrent use of broad-spectrum antibiotic therapy was associated with poorer treatment outcomes in patients receiving immune checkpoint inhibitors for various cancers in...
AACR-NCI-EORTC: Activity of Tipifarnib in Patients With HRAS-Mutant Head and Neck Squamous Cell Carcinoma
A small phase II study investigating the efficacy and safety of the investigational farnesyl transferase inhibitor tipifarnib in patients with recurrent and metastatic HRAS-mutant head and neck squamous cell carcinoma found the agent produced objective responses in the patient population. Based on...
First Survivor Views Survey Highlights Barriers to Addressing Side Effects of Cancer Treatment
Barriers to accessing appropriate therapies to address the physical and psychological side effects of cancer treatment continue to persist for patients and survivors, according to results of the Survivor Views survey conducted by the American Cancer Society Cancer Action Network (ACS CAN)....
Gastrointestinal Cancer Research From ESMO 2019
This week, we discuss two studies in gastrointestinal cancers presented at this year’s European Society for Medical Oncology Congress. First up, the NEOLAP trial assessed induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX followed by surgical exploration in...
ASCO National Cancer Opinion Survey: Cancer Prevention, E-Cigarette, and End-of-Life Knowledge Gaps Reported
One in four Americans say they incorporate cancer prevention into their daily lives, according to ASCO’s third annual National Cancer Opinion Survey, despite research showing that as many as half of all cancer cases are preventable. The survey found low levels of awareness of known cancer risk...
Pembrolizumab for Patients With Advanced Adrenocortical Carcinoma
In a single-center phase II study reported in the Journal of Clinical Oncology, Raj et al found that pembrolizumab showed activity in advanced adrenocortical carcinoma. Study Details Thirty-nine patients with advanced adrenocortical carcinoma were enrolled in the study between February 2016 and...
Trifluridine/Tipiracil Survival Benefit for Patients With Metastatic Gastric Cancer Who Had or Had Not Undergone Prior Gastrectomy
In a subgroup analysis of the phase III TAGS trial (TAS-102 Gastric Study) reported in JAMA Oncology, David H. Ilson, MD, PhD, and colleagues found positive trends in survival benefit with trifluridine/tipiracil treatment vs placebo for patients with pretreated metastatic gastric cancer or...
Top Research From 2019 Quality Care Symposium Focuses on Cost of Cancer Care, Patient Participation in Clinical Trials
The 2019 Quality Care Symposium took place September 6–7, 2019, in San Diego. Abstracts presented at the symposium focused on efforts to improve the quality of care for patients with cancer. Highlights from this year’s meeting included research on the cost of care and patient participation in...
Asciminib/Imatinib in Patients With Previously Treated CML
In a phase I trial, the combination of the BCR-ABL1 inhibitor asciminib and the small-molecule kinase inhibitor imatinib showed preliminary efficacy, safety, and tolerability in patients with chronic myeloid leukemia (CML) resistant to or intolerant of treatment with two or more prior tyrosine...
Dana-Farber Cancer Institute Receives $5 Million Gift to Create the Center for Myelodysplastic Syndromes
A $5 million gift from the Edward P. Evans Foundation will create the Edward P. Evans Center for Myelodysplastic Syndromes (MDS) at Dana-Farber Cancer Institute. The gift will help Dana-Farber in transformative collaborative research aimed at treating, preventing, and ultimately curing MDS....
News in Genitourinary Cancers From ESMO 2019
This week, we discuss two studies in genitourinary cancers presented at the ESMO Congress 2019. The CARD trial investigated treatment with cabazitaxel vs an androgen signaling–targeted inhibitor among patients with metastatic castration-resistant prostate cancer who had disease progression on...
FDA Pipeline: Treatments for HER2-Positive Breast Cancer, AML; Breakthrough Device for Prostate Cancer; Statement on Safety Information for Breast Implants
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to trastuzumab deruxtecan for the treatment of HER2-positive metastatic breast cancer; granted Fast Track designation for bemcentinib for elderly patients with relapsed acute myeloid leukemia (AML); granted Breakthrough...
A Clinical Trial Was the Right Choice for Me
Nothing prepared me for a diagnosis of diffuse large B-cell lymphoma (DLBCL) in the fall of 2016. I had none of the typical symptoms of the cancer, such as night sweats, enlarged lymph nodes, or fatigue. In fact, my energy level was as high as ever, as I traveled around the country for business,...
Addition of Trilaciclib to Chemotherapy in Metastatic Triple-Negative Breast Cancer
In a phase II trial reported in The Lancet Oncology, Tan et al found that the addition of the cell-cycle inhibitor trilaciclib to gemcitabine/carboplatin chemotherapy did not reduce the duration or incidence of severe neutropenia during chemotherapy in women with triple-negative breast cancer. A...
Prior Antibiotic Treatment and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
In a study presented in a brief report in JAMA Oncology, David J. Pinato, MD, PhD, and colleagues found that past—but not concurrent—use of broad-spectrum antibiotic therapy was associated with poorer treatment outcomes in patients receiving immune checkpoint inhibitors for various cancers in...
Two New $1 Million Research Grants Focus on Metastasis of Melanoma
The American Cancer Society and Melanoma Research Alliance have selected two new promising projects in a second round of funding under a partnership between the two organizations. The first grants funded through the partnership, in 2018, focused on advancing research to reduce side effects...
Nab-paclitaxel/Gemcitabine/Cisplatin for Previously Untreated, Advanced Pancreatic Cancer
In a phase Ib/II pilot study reported in JAMA Oncology, Jameson et al found that treatment with nab-paclitaxel, gemcitabine, and cisplatin was active in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Study Details In the study, 25 patients were enrolled between...
The Art of Medicine: Our Role as Patient Advocates
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Pembrolizumab/Lenvatinib in Advanced Endometrial Carcinoma Without Microsatellite Instability–High or Mismatch Repair–Deficient Disease
On September 17, 2019, the combination of pembrolizumab plus lenvatinib was granted accelerated approval for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) and who have disease progression...
FDA Approves Label Expansion for Single-Dose Regimen of Intravenous Aprepitant for Patients Receiving Moderately Emetogenic Chemotherapy
On October 22, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for aprepitant (Cinvanti) injectable emulsion for intravenous (IV) use. The sNDA requested FDA approval to expand the recommended dosage to include the 130-mg single-dose regimen for...
Immunotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Findings from the phase Ib KEYNOTE-013 and phase II KEYNOTE-170 trials reported in the Journal of Clinical Oncology by Armand et al indicated that pembrolizumab is highly active in relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL). The KEYNOTE-170 trial supported the 2018...
2019 NIH Director’s Pioneer Award Recipients in Cancer Research
The National Institutes of Health(NIH) has recently announced the names of two recipients of the 2019 Director’s Pioneer Awards whose research focuses on cell biology: Jennifer H. Elisseeff, PhD, is focusing onregenerative immunotherapies, and Valentina Greco, PhD, is studying the role of stem...
5-Year Follow-up of KEYNOTE-006 Trial of Pembrolizumab vs Ipilimumab in Advanced Melanoma
In a post hoc 5-year follow-up of the KEYNOTE-006 trial reported in The Lancet Oncology, Caroline Robert, MD, of Institut Gustave Roussy, Université Paris-Sud, and colleagues found that pembrolizumab maintained overall and progression-free survival benefits over ipilimumab in advanced melanoma.1 In ...
2019 Supportive Care: Oncology Massage May Relieve Symptoms of Chemotherapy-Induced Peripheral Neuropathy
A new study has found that oncology massage therapy can provide symptomatic relief for a common and difficult-to-treat side effect of cancer treatment. Patients with chemotherapy-induced peripheral neuropathy experienced a sustained reduction in lower-extremity pain up to 6 weeks after completion...
